Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.
Bone Marrow Transplant
; 44(1): 19-25, 2009 Jul.
Article
in En
| MEDLINE
| ID: mdl-19139733
ABSTRACT
There is great interest in chemotherapies for relapsed or refractory lymphomas that are both directly effective against the lymphoma and able to mobilize PBSCs for rescue after high-dose chemotherapy (HDC). Twenty-eight patients with relapsed or refractory lymphomas were treated with a shortened, intensified MJMA regimen (mitoxantrone 10 mg/m(2) i.v. day 1, carboplatin 200 mg/m(2) i.v. days 1-2, methylprednisolone 500 mg/m(2) i.v. days 1-3, cytarabine 2000 mg/m(2) i.v. day 3) for six cycles every 21 days. A median of five cycles/patient was administered. Nineteen patients had complete responses, seven partial responses and two no responses. The only remarkable toxicity was hematological. In 18 patients who were candidates for HDC, a mean of 10.45 x 10(6) CD34/kg of patients' body weight was collected (range 3.70-24.88 x 10(6)/kg). Eleven patients underwent transplantation, which converted two of four partial responses into complete responses. The median follow-up was 49 months. Survival parameters were not related to relapsed/refractory status or to the time from the last chemotherapy, but were related only weakly to the number of prior chemotherapies. Outpatient MJMA is a feasible and very effective salvage chemotherapy per se. The complete response rate is high and it is a powerful PBSC mobilizer.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Hematopoietic Stem Cells
/
Hodgkin Disease
/
Antineoplastic Combined Chemotherapy Protocols
/
Salvage Therapy
/
Hematopoietic Stem Cell Mobilization
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Bone Marrow Transplant
Journal subject:
TRANSPLANTE
Year:
2009
Document type:
Article
Affiliation country:
Italy